title: Interlaboratory and interstudy reproducibility of a novel lateral-flow device and influence of antifungal therapy on detection of invasive pulmonary aspergillosis.
abstract: Interest in lateral-flow devices (LFDs) as potential point-of-care assays for the diagnosis of infectious diseases has increased. Our objective was to evaluate the interlaboratory and interstudy reproducibility and the effects of antifungal therapy on an LFD developed for invasive pulmonary aspergillosis (IPA) detection. An established neutropenic guinea pig model of IPA caused by Aspergillus fumigatus was used. At predetermined time points (1 h and 3, 5, and 7 days postinoculation), blood and bronchoalveolar lavage (BAL) fluid were collected from infected and uninfected animals. In a separate experiment, guinea pigs were treated with posaconazole (10 mg/kg of body weight orally [p.o.] twice a day [BID]), voriconazole (10 mg/kg p.o. BID), liposomal amphotericin B (10 mg/kg intraperitoneally [i.p.] once a day [QD]), or caspofungin (2 mg/kg i.p. QD), and samples were collected on days 7 and 11. Each laboratory independently evaluated the IgG monoclonal antibody-based LFD. Galactomannan and (1 → 3)-β-D-glucan were also measured using commercially available kits. Good interlaboratory agreement was observed with the LFD, as the results for 97% (32/33) of the serum and 78.8% (26/33) of the BAL fluid samples from infected animals were in agreement. Good interstudy agreement was also observed. The serum sensitivity of each surrogate-marker assay was reduced in animals treated with antifungals. In contrast, these markers remained elevated within the BAL fluids of treated animals, which was consistent with the fungal burden and histopathology results. These results demonstrate that the LFD assay is reproducible between different laboratories and studies. However, the sensitivity of this assay and other markers of IPA may be reduced with serum in the presence of antifungal therapy.
authors.affiliation: University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA. wiederholdn@uthscsa.edu
authors.forename: Nathan P
authors.initials: NP
authors.lastname: Wiederhold
authors.forename: Laura K
authors.initials: LK
authors.lastname: Najvar
authors.forename: Rosie
authors.initials: R
authors.lastname: Bocanegra
authors.forename: William R
authors.initials: WR
authors.lastname: Kirkpatrick
authors.forename: Thomas F
authors.initials: TF
authors.lastname: Patterson
authors.forename: Christopher R
authors.initials: CR
authors.lastname: Thornton
mesh_terms: D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage / Q000494:pharmacology; D001230:Aspergillus / Q000187:drug effects / Q000276:immunology / Q000302:isolation & purification; D001992:Bronchoalveolar Lavage Fluid / Q000276:immunology / Q000382:microbiology; D015169:Colony Count, Microbial; D004195:Disease Models, Animal; D005690:Galactose / Q000031:analogs & derivatives; D005936:Glucans / Q000378:metabolism; D006168:Guinea Pigs; D006801:Humans; D055744:Invasive Pulmonary Aspergillosis / Q000175:diagnosis* / Q000188:drug therapy / Q000382:microbiology; D008297:Male; D008351:Mannans / Q000378:metabolism; D019095:Point-of-Care Systems / Q000592:standards; D015203:Reproducibility of Results; D013997:Time Factors
chemical_list: D000935:Antifungal Agents; D005936:Glucans; D008351:Mannans; C012990:galactomannan; D005690:Galactose